http://www.aasraw.com/products/rimonabant-powder/ - Rimonabant is an anorectic anti-obesity drug and Rimonabant powder is the raw material for many weight loss supplement, such as Rimonabant are Zimulti, Acomplia, Monaslim, Bethin, Riobant, Remonabent, Rimoslim and Riomont in the market.Rimonabant powder can help you to loss weight effectively.
Email: firstname.lastname@example.org Whatsapp:+8618928439036 15. Does Rimonabant powder also aid smoking cessation? • Rimonabant powder (Zimulti in the US) was studied by Sanofi-Aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking. • Sanofi-Aventis submitted a New Drug Application to the FDA, which in turn issued a non-approvable letter for rimonabant powder for use in smoking cessation. In June of 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee recommended against the approval of rimonabant powder due to concerns over serious side effects such as suicidality. 16. What were the results of Rimonabant powder clinical trial studies? • In clinical studies, Rimonabant powder was has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss.5,6 • Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Rimonabant powder 20mg was beyond that expected from weight loss alone. • Serious psychological adverse effects, such as suicidality and depression led to the eventual global withdrawal of rimonabant powder by Sanofi-Aventis. 12
Email: email@example.com Whatsapp:+8618928439036 17. Rimonabant for prevention of cardiovascular events (1) Background Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival. (2) Methods This double-blind, placebo-controlled trial was undertaken in 974 hospitals in 42 countries. 18 695 patients with previously manifest or increased risk of vascular disease were randomly assigned to receive either rimonabant 20 mg (n=9381) or matching placebo (n=9314). Randomisation was stratified by centre, implemented with an independent interactive voice response system, and all study personnel and participants were masked to group assignment. The primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke, as determined via central adjudication. Analysis was by 13